$VTGN News

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at Psych Congress 2026

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint

Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Looms

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder